<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04521231</url>
  </required_header>
  <id_info>
    <org_study_id>20180257</org_study_id>
    <secondary_id>2019-004780-52</secondary_id>
    <nct_id>NCT04521231</nct_id>
  </id_info>
  <brief_title>A Study of Subcutaneous Blinatumomab Administration in Acute Lymphoblastic Leukemia (ALL) Patients</brief_title>
  <official_title>A Phase 1b Open-label Study to Investigate the Safety and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Adults With Relapsed or Refractory B Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to evaluate the safety and tolerability of subcutaneous (SC) blinatumomab for&#xD;
      treatment of Acute Lymphoblastic Leukemia (ALL) and to determine the maximum tolerated dose&#xD;
      (MTD), and recommended phase 2 dose (RP2D) of SC administered blinatumomab.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 4, 2021</start_date>
  <completion_date type="Anticipated">April 8, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 10, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants who experience dose limiting toxicities (DLTs)</measure>
    <time_frame>Up to 29 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants who experience one or more treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>Up to approximately 25 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants who experience one or more serious treatment-emergent adverse event (TEAEs)</measure>
    <time_frame>Up to approximately 25 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants who experience one or more treatment-related treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>Up to approximately 25 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants who experience one or more adverse events (AEs)</measure>
    <time_frame>Up to approximately 25 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Minimum concentration over the dosing interval (Cmin) of blinatumomab</measure>
    <time_frame>Up to 68 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum concentration (Cmax) of blinatumomab</measure>
    <time_frame>Up to 68 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach maximum concentration (Tmax) of blinatumomab</measure>
    <time_frame>Up to 68 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve (AUC) of blinatumomab</measure>
    <time_frame>Up to 68 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with incidence of anti-blinatumomab antibody formation</measure>
    <time_frame>Up to 68 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of complete remission (CR) including complete remission with partial hematological recovery (CRh)</measure>
    <time_frame>Up to 68 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>B Cell Precursor Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>Blinatumomab: Dose escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohorts of at least 3 participants each will be treated with escalating doses of blinatumomab to determine the maximum tolerated dose (MTD). The MTD will be defined as the dose for which the estimate of the toxicity rate from an isotonic regression (Yan et al, 2017) is closest to the target toxicity rate. Safety, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy will be assessed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Blinatumomab: Dose expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be administered the recommend phase 2 dose (RP2D) determined from dose escalation stage to further assess safety, pharmacokinetics (PK), pharmacodynamic (PD), and efficacy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Blinatumomab</intervention_name>
    <description>Blinatumomab will be administered as a subcutaneous (SC) injection.</description>
    <arm_group_label>Blinatumomab: Dose escalation</arm_group_label>
    <arm_group_label>Blinatumomab: Dose expansion</arm_group_label>
    <other_name>AMG 103</other_name>
    <other_name>Blincyto®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged 18 years or older.&#xD;
&#xD;
          -  Participants with B-precursor ALL with Relapsed or Refractory disease with any of the&#xD;
             following:&#xD;
&#xD;
               -  Refractory to primary induction therapy or refractory to salvage therapy&#xD;
&#xD;
               -  In untreated first, second, third or greater relapse or refractory relapse&#xD;
&#xD;
                    -  First Relapse is defined as achievement of first Complete Remission (CR)&#xD;
                       [CR1] during upfront therapy then relapse during or after continuation&#xD;
                       therapy&#xD;
&#xD;
                    -  Primary Refractory disease is defined as the absence of CR after standard&#xD;
                       induction therapy&#xD;
&#xD;
                    -  Refractory relapse is defined as lack of CR after salvage treatment&#xD;
&#xD;
                    -  Second relapse or later relapse is defined&#xD;
&#xD;
          -  Relapsed or Refractory at any time after first salvage therapy or refractory relapse.&#xD;
&#xD;
          -  Relapse at any time after allogenic hematopoietic stem cell transplant (HSCT).&#xD;
&#xD;
          -  Greater than or equal to 5% blasts in the Bone Marrow.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status less than or equal to 2.&#xD;
&#xD;
          -  Participants with relapse or refractory B Cell ALL Ph+ disease and that are intolerant&#xD;
             or refractory to prior tyrosine kinase inhibitors (TKIs) are eligible.&#xD;
&#xD;
          -  Participants with CR2 or greater with a BM blast count of at least 0.1% (10-3).&#xD;
&#xD;
        The above is a summary, other inclusion criteria details may apply.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active ALL in the central nervous system (CNS). Presence of greater than 5 white blood&#xD;
             cells per cubic millimeter in cerebrospinal fluid (CSF) with lymphoblasts present and&#xD;
             or clinical signs of CNS leukemia.&#xD;
&#xD;
          -  History or presence of clinically relevant CNS pathology such as epilepsy, childhood&#xD;
             or adult seizure, paresis, aphasia, stroke, severe brain injuries, dementia,&#xD;
             Parkinson's disease, cerebellar disease, organic brain syndrome or psychosis.&#xD;
&#xD;
          -  Symptoms and/or signs that indicate an acute or uncontrolled chronic infection.&#xD;
&#xD;
          -  History of malignancy (with certain exceptions) other than ALL within 3 years prior to&#xD;
             start of protocol-specified therapy.&#xD;
&#xD;
          -  Allogeneic HSCT within 12 weeks before the start of protocol-specified therapy.&#xD;
&#xD;
          -  Cancer chemotherapy within 2 weeks before the start of protocol-specified therapy.&#xD;
&#xD;
          -  Immunotherapy within 4 weeks before start of protocol-specified therapy. Prior failed&#xD;
             CD19 directed therapy such as prior blinatumomab or CD19 CAR T cells will be allowed,&#xD;
             if treatment ended more than 4 weeks prior to start of protocol therapy.&#xD;
&#xD;
          -  Currently receiving treatment in, or less than 30 days since ending treatment on&#xD;
             another investigational study(ies).&#xD;
&#xD;
          -  Abnormal screening laboratory parameters&#xD;
&#xD;
          -  Female participant: Expected to breastfeed during treatment and for 96 hours after the&#xD;
             last dose of treatment.&#xD;
&#xD;
        The above is a summary, other exclusion criteria details may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amgen Call Center</last_name>
    <phone>866-572-6436</phone>
    <email>medinfo@amgen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1023</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1023</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Allgemeines Krankenhaus Wien</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Regional Universitaire de Lille - Hopital Claude Huriez</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Nice</name>
      <address>
        <city>Nice cedex 3</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire du Cancer Toulouse Oncopole</name>
      <address>
        <city>Toulouse cedex 9</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Charite Universitätsmedizin Berlin Campus Benjamin Franklin</name>
      <address>
        <city>Berlin</city>
        <zip>12200</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Leipzig Anstalt des oeffentlichen Rechts</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Tubingen</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII</name>
      <address>
        <city>Bergamo</city>
        <zip>24127</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia</name>
      <address>
        <city>Brescia</city>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>IRCCS Ospedale San Raffaele</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Policlinico Umberto I</name>
      <address>
        <city>Roma</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <state>Castilla León</state>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinica Universidad de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 18, 2020</study_first_submitted>
  <study_first_submitted_qc>August 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2020</study_first_posted>
  <last_update_submitted>August 27, 2021</last_update_submitted>
  <last_update_submitted_qc>August 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>R/R B-ALL</keyword>
  <keyword>Blincyto®</keyword>
  <keyword>AMG 103</keyword>
  <keyword>Blinatumomab</keyword>
  <keyword>Acute lymphoblastic leukemia (ALL)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Blinatumomab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.</ipd_time_frame>
    <ipd_access_criteria>Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.</ipd_access_criteria>
    <ipd_url>https://www.amgen.com/datasharing</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

